Plant Health Care PLC PHC398 Approved by US EPA: PHC279 submitted to EPA (0288Q)
16 Junio 2020 - 1:00AM
UK Regulatory
TIDMPHC
RNS Number : 0288Q
Plant Health Care PLC
15 June 2020
RNS
15 June 2020
PLANT HEALTH CARE plc
("Plant Health Care" or the "Company")
PHC398 Approved by US EPA and PHC279 submitted to US EPA
Plant Health Care(R) , a leading provider of novel
patent-protected biological products to global agriculture markets,
is pleased to announce the US EPA has approved its application for
the novel peptide product, PHC398.
Highlights:
- PHC398 is the first active ingredient from Plant Health Care's
PREtec technology platform approved for registration anywhere in
the world.
- The registration of PHC398 makes the process of registering
future PREtec products in the US quicker and cheaper.
- The high-performance variant of PHC398, known as PHC279, was
submitted for EPA approval on May 14th, 2020 and is currently
expected to be approved in the second half of 2021.
Plant Health Care's PREtec peptides represent a novel class of
technology to stimulate the plant to defend itself. Derived from
natural proteins, PREtec is an environmentally friendly approach to
protecting crops and increasing yields, and is compatible with
mainstream agricultural practice. Whether applied as a seed
treatment or foliar spray, PREtec peptides promote plant health,
suppress disease and soil nematodes, and increase yield. PREtec may
allow farmers to reduce applications of less safe chemical
fungicides and to achieve better control of damaging plant
diseases.
Plant Health Care has now submitted PHC279 for approval by the
US EPA for use on a wide range of row crops (such as corn and
soybeans) and fruit and vegetable crops; this will be the first of
a series of peptides the Company intends to commercialize over the
next two to three years.
Chris Richards, CEO of Plant Health Care, said "We are very
pleased to have achieved this first registration of a PREtec
peptide. The EPA's positive review on PHC398 greatly increases the
probability that future peptides from the PREtec platform will be
registered quickly and at low cost. The first commercial product in
line for registration is PHC279 which has generated strong results
from testing in 2019 in the US and Brazil. We are excited about the
potential for products based on our PREtec peptides, which are
targeting markets valued at $5 billion."
For further information, please contact:
Plant Health Care plc
Chris Richards, CEO Tel: +1 919 926 1600
Arden Partners plc - Nomad & Broker
John Llewellyn-Lloyd / Dan Gee-Summons Tel: +44 (0) 20 7614
5900
Company website: www.planthealthcare.com
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
REAKZGMVNKZGGZM
(END) Dow Jones Newswires
June 16, 2020 02:00 ET (06:00 GMT)
Plant Health Care (LSE:PHC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Plant Health Care (LSE:PHC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024